vedolizumab

Generic Name: vedolizumab

Brand Name: Entyvio

Manufacturer: Takeda Canada Inc.

Therapeutic Area: Crohn’s disease

Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

Manufacturer Requested Reimbursement Criteria¹: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNF antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Date Recommendation Issued: January 21, 2021

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule C

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.